Biochemistry

Mauro Vasella

Mauro Vasella

Set of flashcards Details

Flashcards 288
Language English
Category Medical
Level University
Created / Updated 02.03.2015 / 27.03.2020
Weblink
https://card2brain.ch/box/usmle_step_1_biochemistry_other
Embed
<iframe src="https://card2brain.ch/box/usmle_step_1_biochemistry_other/embed" width="780" height="150" scrolling="no" frameborder="0"></iframe>

Chromatin structure

  • negative DNA loops twice around positively charged histone octamer, which then forms the nucleosome core (H2A, H2B, H3, H4)
  • H1 ties beads together

  1. Heterochromatin
  2. Euchromatin

  1. condensed, inactive, inaccessible
  2. less condensed, active, accessible

  1. Methylation
  2. Hypermethylation
  3. Acetylation

  1. C-G base pairs on the template strand are methylated –> allows mismatch repair enzymes to distinguish between old & new strands
  2. inactivates transcription of DNA
  3. relaxes DNA coiling –>  transcription

  1. Purines
  2. Pyrimidines
  3. Bonds

  1. 2 rings
    1. Adenosine
    2. Guanine: has a ketone
    3. Amino acides necessary for purine synthesis: glycine, aspartate, glutamine
  2. 1 rings
    1. Thymine: has a methyl; in DNA
    2. Cytosine: becomes uracil when deaminated
    3. Uracil: in RNA
  3. Bonds
    1. G-C bond stronger (3H)
    2. A-T bond (2H)

  1. Nucleoside
  2. Nucleotide

  1. Base + ribose
  2. Base + ribose + phosphate

De novo pyrimidine and purine synthesis

  • Purines:
    • start with sugar + phosphate (PRPP)
    • add base
  • Pyrimidines:
    • make temporary base (orotic acid)
    • add sugar + phosphate (PRPP)
    • modify base

Antineoplastic and antibiotic drugs interfering with nucleotide synthesis (5)

  • Hydroxyurea: inhibits ribonucleotide reductase
  • 6-mercaptopurine: blocks de novo purine synthesis
  • 5-fluorouracil: inhibits thymidylate synthase (dTMP decreased)
  • Methotrexate: inhibits dihydrofolate reductase (dTMP decreased)
  • Trimethoprim: inhibits bacterial dihydrofolate reductase (dTMP decreased)

Orotic aciduria

  1. Definition
  2. Findings (4)
  3. Treatment

  1. Inability to convert orotic acid to UMP
    1. due to defect in either orotic acid phosphoribosyltransferase or orotidine 5'-phosphate decarboxylase
    2. autosomal recessive
  2. Findings
    1. increased orotic acid in urine
    2. megaloblastic anemia
    3. failure to thrive
    4. No hyperammonemia
  3. Treament: oral uridine administration

Purine salvage & salvage deficiencies

  • Adenosine deaminase deficiency
    • excess ATP and dATP imbalances nucleotide pool via feedback inhibition of ribonucleotide reductase –> prevents DNA synthesis and thus decreases lymphocyte count –> SCID (severe comined immunodeficiency disease)
  • Lesch-Nyhan syndrome
    • absence of HGPRT –> excess of uric acid production & de novo purine synthesis
    • findings: retardation, self-mutilation aggression, hyperuricemia, gout, choreoathetosis
    • x-linked recessive

Mutations in DNA (4)

  • Silent: same aa, often base change in 3rd position of codon
  • Missense: changed aa (conservative - new aa is similar in chemical structure)
  • Nonsense: change resulting in early stop codon (UAA, UGA, UAG)
  • Frame shift: change resulting in misreading of all nucleotides downstream, usually resulting in a truncated, nonfunctional protein

  1. Helicase
  2. DNA topoisomerases
  3. Primase
  4. DNA polymerase I
  5. DNA polymerase III
  6. DNA ligase
  7. Telomerase

  1. Unwinds DNA template at replication fork
  2. Create a nick in the helix to relieve supercoils created during replication
  3. Makes an RNA primer on which DNA ppolymerase III can initiate replication
  4. Prokaryotic only. Degrades RNA primer and fills in the gap with DNA
  5. Prokaryotic only. Has 5' –> 30 synthesis and proofreads with 3' –> 5' exonuclease
  6. Seals
  7. Enzyme adds DNA to 3' ends of chromosomes to avoid loss of genetic material with every duplication

Single strand DNA repair (3)

  • Nucleotide exicision repair: mutated in xeroderma pigmentosum
    • specific endonucleases release the oligonucleotide-containing damaged bases
    • DNA polymerase and ligase fill and reseal the gap, respectively
  • Base excision repair:
    • specific glycosylases recognize and remove damaged bases
    • AP endonuclease cuts DNA at apyrimidinic site
    • empty sugar is removed
    • gap is filled and resealed
  • Mismatch repair: mutated in HNPCC
    • Unmethylated, newly synthesized string is recognized
    • mismatched nucleotides are removed
    • gap is filled and resealed

Double strand DNA repair

  • Nonhomologous end joining: mutated in ataxia telangiectasia
    • brings together 2 ends of DNA fragments
    • no requirements for homology

  1. mRNA start codons
  2. mRNA stop codons

  1. AUG
    • Eukaryotes: codes for methionine
    • Prokaryotes: codes for formyl-methionine
  2. UGA, UAG, UAA

RNA polymerases

  1. Eukaryotes
  2. Prokaryotes

  1. Eukaryotes
    • RNA polymerase I makes rRNA
    • RNA polymerase II makes mRNA (opens DNA at promoter site); alpha-amanitin (death cap mushrooms) inhibits RNA polymerase II –> liver failure
    • RNA polymerase III makes tRNA
    • No proofreading function, but can initiate chains
  2. Prokaryotes
    • 1 RNA polymerase (multisubunit complex) makes all 3 kinds of RNA

RNA processing (eukaryotes)

  1. Capping on 5' end (addition of 7-methylguanosine occurs in cytosol)
  2. Polyadenylation on 3' end (ca. 200 A's)
  3. Splicing out of introns

       = mRNA

 

Disease in which antibodies against spliceosomal snRNPs are found

Lupus

Lac operon

when active, E. coli can metabolize lactose

  • Lactose inhibits the repressor
  • Glucose inhibits the activator

tRNA

  1. Structure
  2. Charging

  1. Structure
    • 75-90 nucleotides
    • secondary structure, cloverleaf form
    • anticodon end is opposite 3' aminoacyl end
    • all tRNAs have CCA at 3' end
    • aa is covalently bound to the 3' end of the tRNA
  2. Charging
    • Aminoacly-tRNA synthetase (1 per aa, uses ATP)
    • aa-tRNA bond has energy for formation of peptide bond
    • a mischarged tRNA reads usual codon but inserts wrong amino acid

Tetracyclines bind 30S subunit, preventing attachment of aminoacyl-tRNA

Protein synthesis

  1. Initiation
  2. Elongation
  3. Termination

  1. Initiation
    • Activated by GTP hydrolysis
    • initiation factors help assemble the 40S ribosomal subunit with the initiator tRNA
    • Ribosom: eukaryotes (40S + 60S –> 80S), prokaryotes (30S + 50S –> 70S)
    • ATP –> charging of tRNA; GTP –> tRNA gripping
  2. Elongation
    1. Aminoacyl-tRNA binds to A site
    2. Ribosomal rRNA catalyzes peptide bond formation, transfers growing polypeptide to amino acid in A site
    3. Ribosome advances 3 nucleotides toward 3' end of RNA, moving peptidyl RNA to P site
  3. Termination
    • Stop codon ist recognized by release factor, and completed protein is released from ribosome

Antibiotics which act as protein synthesis inhibitors (4)

  • Aminoglycosides: binds 30S and inhibit formation of the initiation cpmplex and cause misreading of mRNA
  • Chloramphenicol inhibits 50S peptidyltransferase
  • Macrolides block translocation
  • Clindamycin and chloramphenicol block peptide bond formation

Posttranslational modifications (3)

  • Trimming: removal of N- or C-terminal propeptides from zymogens to generate mature proteins
  • Covalent alterations: phosphorylation, glycosylation, and hydroxylation
  • Proteasomal degradation: attachment of ubiquitin to defective proteins to tag them for breakdown

  1. Cell cycle phases
  2. Regulation of cell cycle

  1. Picture
  2. Regulation
    • CDKs (Cyclin dependent kinases): constitutive and inactive
    • Cyclins: Regulatory proteins that control cell cycle events; phase specific; activate CDKs
    • Cyclin-CDK complexes: Must be both activated and inactivated for cell cycle to progress
    • Tumor suppressors: Rb and p53 normally inhibit G1 to S progression; mutations in these genes result in unrestrained growth

Cell types (3)

  • Permanent: remain in G0, regenerate from stem cells.
    • Neurons, skeletal and cardiac muscle, RBCs
  • Stable: enter G1 from G0 when stimulated.
    • Hepatocytes, lymphocytes
  • Labile: never go to G0, divide rapidly with a short G1
    • Bone marrow, gut epithelium, skin, hair follicles

RER

  • Site of synthesis of secretory proteins and of N-linked oligosaccharide addition to many proteins
  • Nissl bodies (RER in neurons) synthesize enzymes and peptide neurotransmitters
  • Mucus-secreting goblet cells of the small intestine and antibody-secreting plasma cells are rich in RER

SER

  • Site of steroid synthesis and detoxification of drugs and poisons
  • Liver hepatocytes and steroid hormone-producing cells of the adrenal cortex are rich in SER

  1. Cell trafficking
  2. Vesicular trafficking proteins

  1. Golgi = distribution center
    • modifies N-oligosaccharides on asparagine
    • adds O-oligosaccharides on serine and threonine
    • adds mannose-6-P to proteins for trafficking to lysosomes
  2.  
    • COP1: retrograde, Golgi –> ER
    • COP2: anterograde, RER –> cis-Golgi
    • Clathrin: trans-Golgi –> lysosomes, plasma membrane –> endosomes

I-cell disease

  • inherited lysosomal storage disorder
  • failure of addition of mannose-6-P to lysosome proteins
  • coarse facial features, clouded corneas, restricted joint movement, high plasma levels of lysosomal enzymes
  • often fatal in childhood

Peroxisome

membrane-enclosed organelle involved in catabolism of very long fatty acids and amino acids

Proteasome

Barrel-shaped protein complex that degrades damaged or unnecessary proteins tagged for destruction with ubiquitin

Microtubule

  • Cylindrical structure composed of a helical array of polymerized dimers of alpha- & beta-tubulin
  • Each dimer has 2 GTP bound
  • involved in slow axoplasmatic transport in neurons
  • Dynein: retrograde to microtubule (+ –> -)
  • Kinesin: anterograde to microtubule (- –> +)

Drugs that act on microtubules (5)

  1. Mebendazole/thiabendazole (antihelminthic)
  2. Griseofulvin (antifungal)
  3. Vincristine/vinblastine (anti-cancer)
  4. Paclitaxel (anti-breast cancer)
  5. Colchicine (anti-gout)

Chédiak-Higashi syndrome

  • microtubule polymerization defect resulting in decreased fusion of phagosomes and lysosomes
  • recurrent pyogenic infections, partial albinism, peripheral neuropathy

Cilia structure

  • 9+2 arrangement of microtubules
  • Axonemal dynein-ATPase that links peripheral 9 doublets

Kartagener's syndrome

  • immotile cilia due to a dynein arm defect
  • male & female infertility
  • bronchiectasis, recurrent sinusitis
  • associated with situs inversus

Plasma membrane composition

  • asymmetric lipid bilayer
  • contains cholesterol (ca. 50%), phospholipids (ca. 50%), sphingolipids, gylcolipids and proteins.
  • high cholesterol or long saturated fatty acid content –> increased melting temperature, decreased fluidity

Immunohistochemical stains for intermediate filaments

  1. Connective tissue
  2. Muscle
  3. epithelial cells
  4. neuroglia
  5. neurons

  1. Vimentin
  2. Desmin
  3. Cytokeratin
  4. GFAP
  5. Neurofilaments

Sodium pump

  • Na+-K+ ATPase is located in the plasma membrane with ATP site on cytoplasmic side
  • for each ATP consumed 3 Na+ go out and 2 K+ come in
  • during cycle, pump is phosphorylated

  1. Ouabain
  2. Cardiac glycosides (digoxin)

  1. inhibts by binding to K+ site
  2. directly inhibits the Na+-K+ ATPase, which leads to indirect inhibition of Na+/Ca2+ exchange

Collagen

  1. Type I (90%): bone, skin, tendon, dentin, fascia, cornea, late wound repair
  2. Type II: cartilage, vitreous body. nucleus pulposus
  3. Type III (reticulin): skin, blood vessels, uterus, fetal tissue, granulation tissue
  4. Type IV: basement membrane or basal lamina